Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

BACKGROUND: The sodium‐glucose cotransporter 2 inhibitor canagliflozin reduced the risk of first cardiovascular composite events in the CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial. In this post hoc analysis, we evaluated the effect of...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jing‐Wei, Arnott, Clare, Heerspink, Hiddo J. L., MBiostat, Qiang Li, Cannon, Christopher P., Wheeler, David C., Charytan, David M., Barraclough, Jennifer, Figtree, Gemma A., Agarwal, Rajiv, Bakris, George, de Zeeuw, Dick, Greene, Tom, Levin, Adeera, Pollock, Carol, Zhang, Hong, Zinman, Bernard, Mahaffey, Kenneth W., Perkovic, Vlado, Neal, Bruce, Jardine, Meg J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496296/
https://www.ncbi.nlm.nih.gov/pubmed/35929472
http://dx.doi.org/10.1161/JAHA.121.025045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496296/
https://www.ncbi.nlm.nih.gov/pubmed/35929472
http://dx.doi.org/10.1161/JAHA.121.025045

Ejemplares similares